Global Continuous Bioprocessing Market Size (2024 - 2029)

The continuous bioprocessing market is projected to experience significant growth, driven by the increasing adoption of continuous processing technologies and advancements in biomanufacturing. This market expansion is supported by the rising demand for biopharmaceuticals, fueled by the growing prevalence of chronic diseases and strategic investments in the sector. The use of flexible infrastructures in biomanufacturing is enhancing efficiency and reducing costs, further contributing to market growth. However, challenges such as stringent regulations and high equipment costs may impede the market's expansion.

Market Size of Global Continuous Bioprocessing Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Continuous Bioprocessing Market Size
Study Period 2019 - 2029
Market Size (2024) USD 201.81 Million
Market Size (2029) USD 574.41 Million
CAGR (2024 - 2029) 23.27 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Global Continuous Bioprocessing Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Continuous Bioprocessing Market Analysis

The Global Continuous Bioprocessing Market size is estimated at USD 201.81 million in 2024, and is expected to reach USD 574.41 million by 2029, growing at a CAGR of 23.27% during the forecast period (2024-2029).

In recent times, countries have faced a huge threat of COVID-19. As per the World Health Organization (WHO), coronavirus disease is an infectious disease, and most people infected with the COVID-19 virus will experience mild to moderate respiratory illness. Most pharmaceutical and biotechnological companies have reallocated their resources in research and development (R&D) departments toward identifying new molecules or leads for the treatment of COVID-19. This has impacted the research and development activities of biopharmaceuticals for other chronic diseases. In the early phase of the pandemic, due to the lockdown measures, trade restrictions, and high infection rate, many pharmaceutical and biotechnology companies were hit, and their work was impacted, especially R&D activities, as the clinical and other types of trials were delayed by more than six months.

According to the study 'Impact of COVID19 on Operational Activities of Manufacturing Organizations-A Case Study and Industry 4.0-Based Survive-Stabilise-Sustainability (3S) Framework,' published in March 2021, restrictions imposed by local authorities have had the highest impact on operational activities, followed by unavailability of transport and unavailability of workers; scarcity of raw materials increased workload and decrease in working days have had a significant impact on the biopharmaceutical organizations. increase in machine failures, overproduction, and insufficient production to fulfill demand, also had an impact on operational activities, thus leaving a significant impact on the market.

The factors propelling the studied market growth are the growing adoption of continuous processing, increasing technological advancements in the continuous processing space, and increasing demand for biopharmaceuticals. Along with it, increasing investments and government initiatives boosting biomanufacturing will also contribute positively to market growth.

Continuous bioprocessing is being readily adopted as one of the future forms of biomanufacturing production because it operates on the same scale in both clinical production and commercialization, using flexible infrastructure that can respond quickly to changing market pressures. The use of flexible infrastructures such as single-use flow paths and small surgical vessels with the same bioreactor size will reduce significant investment while making technology transfer operations easier and maintaining quality profiles. Additionally, the rising burden of chronic diseases such as cancer, neurological disorders, cardiovascular diseases, rare diseases, and others will propel the demand for biopharmaceuticals, thereby driving the continuous bioprocessing market. For instance, as per the 2020 statistics by GLOBOCAN 2020, an estimated number of 19,292,789 people were diagnosed with cancer in 2020. As per the same source mentioned above, the number of people suffering from cancer is estimated to reach 30.2 million by 2040. Thus, the growing burden of cancer globally will significantly increase the demand for biosimilars, thus driving the market.

Moreover, rising investments in the studied market will also lead to lucrative growth of the market. For instance, in September 2021, Gamma Biosciences made a strategic investment in Nirrin Technologies, a provider of next-generation sensors and analytics for real-time, in-process monitoring and analysis in upstream and downstream bioprocessing applications and continuous processing for the biopharma and life science industries. However, strict regulations for continuous bioprocessing and high equipment costs are expected to hinder the market growth.

Continuous Bioprocessing Industry Segmentation

As per the scope of the report, the manufacturing of a production unit is considered continuous if it is able to process continuous flow inputs for a long period of time. The output may be continuous or split into smaller packets generated in a circular manner. The continuous bioprocessing market is segmented by product (filtration systems and consumables, chromatography systems and consumables, bioreactors, sterilizers, centrifuges, and others (incubators and shakers, cell culture media, buffers and reagents, and consumables)), by application (commercial and research and development), by end-user (pharmaceutical and biotechnology companies, CDMOs and CROs, academic and research institutes), and geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report offers the value (in USD million) for the above segments. The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Product
Filtration Systems and Consumables
Chromatography Systems and Consumables
Bioreactors
Sterilizers
Centrifuges
Others (Incubators and Shakers, Cell Culture Media, Buffers and Reagents and Consumables)
By Application
Commercial
Research and Development
By End User
Pharmaceutical and Biotechnology Companies
CDMOs and CROs
Academic and Research Institutes
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Continuous Bioprocessing Market Size Summary

The continuous bioprocessing market is poised for significant expansion, driven by the increasing adoption of continuous processing technologies and advancements in biomanufacturing. This market is gaining traction due to its ability to operate efficiently at both clinical and commercial scales, utilizing flexible infrastructures that adapt to market demands. The rising prevalence of chronic diseases, such as cancer and cardiovascular disorders, is fueling the demand for biopharmaceuticals, thereby propelling the growth of continuous bioprocessing. Additionally, strategic investments and government initiatives aimed at enhancing biomanufacturing capabilities are contributing positively to the market's trajectory. Despite challenges such as stringent regulations and high equipment costs, the market is expected to experience robust growth, supported by technological innovations and increased research and development activities.

In North America, particularly the United States, the continuous bioprocessing market is expected to hold a significant share due to the high burden of chronic diseases and the establishment of advanced bioprocessing facilities. The region's market growth is further bolstered by strategic partnerships and investments in continuous manufacturing technologies, which are enhancing production efficiencies and reducing costs. Major players in the market, including 3M, Thermo Fisher Scientific, and Merck KGaA, are actively involved in driving innovation and expanding their market presence. The competitive landscape is characterized by significant investments in research and development, aimed at advancing continuous bioprocessing technologies and meeting the growing demand for biopharmaceuticals. As the market evolves, it is expected to lead to substantial growth, with continuous bioprocessing emerging as a key component of the biomanufacturing industry.

Explore More

Global Continuous Bioprocessing Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Growing Adoption of Continuous Bioprocessing

      2. 1.2.2 Increasing Demand for Biopharmaceuticals

      3. 1.2.3 Technological Advancements in Continous Bioprocessing Space

    3. 1.3 Market Restraints

      1. 1.3.1 Strict Regulations for Continuous Bioprocessing Coupled with High Equipment Cost

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD Million)

    1. 2.1 By Product

      1. 2.1.1 Filtration Systems and Consumables

      2. 2.1.2 Chromatography Systems and Consumables

      3. 2.1.3 Bioreactors

      4. 2.1.4 Sterilizers

      5. 2.1.5 Centrifuges

      6. 2.1.6 Others (Incubators and Shakers, Cell Culture Media, Buffers and Reagents and Consumables)

    2. 2.2 By Application

      1. 2.2.1 Commercial

      2. 2.2.2 Research and Development

    3. 2.3 By End User

      1. 2.3.1 Pharmaceutical and Biotechnology Companies

      2. 2.3.2 CDMOs and CROs

      3. 2.3.3 Academic and Research Institutes

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Global Continuous Bioprocessing Market Size FAQs

The Global Continuous Bioprocessing Market size is expected to reach USD 201.81 million in 2024 and grow at a CAGR of 23.27% to reach USD 574.41 million by 2029.

In 2024, the Global Continuous Bioprocessing Market size is expected to reach USD 201.81 million.

Continuous Bioprocessing Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)